Virax Biolabs Group Ltd (VRAX)

Virax Biolabs Group Ltd is a healthcare company listed on NASDAQ under the ticker VRAX. The company develops and distributes diagnostic products focused on viral disease prevention, detection, diagnosis, and risk management, with an emphasis on T cell in vitro diagnostics. Its product range includes ViraxClear-branded test kits covering areas such as respiratory, pregnancy and fertility, infectious diseases, sexually transmitted infections, drugs of abuse, oncology, cardiac, and women’s health diagnostics, along with ViraxVet rapid and molecular tests for small-animal veterinary use. Virax Biolabs also provides ViraxImmune, a T cell in vitro diagnostic device paired with a wellness mobile application, and offers services including antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology laboratory services, and related kits and reagents. The company also conducts research and development and supports procurement, warehousing, product development, and staffing management activities. It serves research organizations, corporations, independent laboratories, hospital systems, and public and private institutions across the United Kingdom, the United States, and China.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.